Journal profile · Psychology-Clinical Psychology
Neuropsychopharmacology Reports
ISSN 2574-173X · Wiley-Blackwell · Australia
Neuropsychopharmacology Reports: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.9 (journal website); fully open access; APC about USD 2,500; median 114 days to acceptance (89 articles, last 24 months); acceptance rate 77% (journal website); 105 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Neuropsychopharmacology Reports is published by Wiley-Blackwell and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Schizophrenia research and treatment, Neurotransmitter Receptor Influence on Behavior and Treatment of Major Depression, together about 29.3% of its articles. Its main subfields are Psychiatry and Mental health. (generated from OpenAlex topic counts and CAS ranking data)
Neuropsychopharmacology Reports, the official publication of the Japanese Society of Neuropsychopharmacology and the Japanese Society of Clinical Neuropsychopharmacology, publishes articles on all aspects of neuropsychopharmacology and its related fields in the following categories: Review Articles, Original Articles, Micro Reports and Case Reports. Other categories may be occasionally set for invited articles. The official journal of the Japanese Society of Neuropsychopharmacology was formerly known as the Japanese Journal of Neuropsychopharmacology (indexed by Medline ) and is now reborn as an Open Access journal, Neuropsychopharmacology Reports starting from 2018. Abstracting and Indexing Information ArticleFirst (OCLC) Biological Abstracts (Clarivate Analytics) BIOSIS Previews (Clarivate Analytics) Embase (Elsevier) Emerging Sources Citation Index (Clarivate Analytics) Health Research Premium Collection (ProQuest) Health & Medical Collection (ProQuest) MEDLINE/PubMed (NLM) ProQuest Central (ProQuest) SCOPUS (Elsevier) Web of Science (Clarivate Analytics) Neuropsychopharmacology Reports
From the journal's Aims & Scope
Research area (LetPub): Psychology-Clinical Psychology
Editor-in-chief Tsuyoshi MiyakawaPublisher website
Editorial board by country: none in mainland China; most named Japan 30, United States 5, Taiwan, China 2, Germany 2, Italy 2 (44 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Schizophrenia research and treatmentMedicine13.8%
- Neurotransmitter Receptor Influence on BehaviorNeuroscience7.7%
- Treatment of Major DepressionMedicine7.7%
- Tryptophan and brain disordersNeuroscience6.1%
- Attention Deficit Hyperactivity DisorderMedicine5.5%
- Sleep and related disordersPsychology5%
- Bipolar Disorder and TreatmentMedicine5%
- Substance Abuse Treatment and OutcomesMedicine4.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Neurosciences | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
| Minor | Psychiatry | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Neurosciences | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
| Minor | Psychiatry | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceMEDLINEPubMedEmbasePublisher website
Other: ProQuest, OCLC
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 1.9Publisher website ·
- Impact factor (publisher) 2025
- 1.9Publisher website ·
- CiteScore 2026-06
- 2.9LetPub ·
- CiteScore (publisher)
- 2.9Publisher website ·
- CiteScore (publisher) 2025
- 2.9Publisher website ·
- SJR 2026-06
- 0.56LetPub ·
- SNIP 2026-06
- 0.58LetPub ·
- h-index
- 31OpenAlex ·
- i10-index
- 170OpenAlex ·
- 2-year mean citedness
- 2.45OpenAlex ·
- Self-citation rate
- 5.3%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 86LetPub ·
- Articles per year (publisher) 2025
- 94Publisher website ·
- Downloads per year (publisher) 2025
- 293,745Publisher website ·
Articles by year OpenAlex count · 737 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 93 | 93 | 20 |
| 2025 | 105 | 105 | 234 |
| 2024 | 112 | 112 | 507 |
| 2023 | 103 | 103 | 686 |
| 2022 | 88 | 88 | 696 |
| 2021 | 74 | 74 | 1,098 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
114 daysMedian, submission to acceptance · P25–P75 82 days – 192 days
- Acceptance to online
- median 16 days (89 articles)
- Submission to online
- median 133 days
- Sample
- 89 articles with submission and acceptance dates (223 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 14 weeksLetPub ·
- Acceptance rate (publisher)
- 77%Publisher website ·
- Acceptance rate (publisher) 2025
- 77%Publisher website ·
- Submission to first decision
- 35 daysPublisher website ·
- Submission to first decision 2025
- 35 daysPublisher website ·
- Submission to acceptance 2025
- 113 daysPublisher website ·
- Acceptance to publication 2025
- 17 daysPublisher website ·
- Submission to publication (journal-reported)
- about 14 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,500 / GBP 1,920 / EUR 2,300 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 2,500 / EUR 2,300 / GBP 1,920 | — | — | |
| LetPub | USD 2,280 / GBP 1,757 / EUR 2,093 | Yes | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare7 items from the author guidelines
- Abstract
- ≤ 250 words
- Manuscript length
- ≤ 4,000 words
- Reference style
- Author–date
- Suggested reviewers
- Optional
- Highlights
- Required
- Graphical abstract
- Optional
- Cover letter
- Required
Article types accepted11, with length limits
- case reportin either basic or clinical science. C. Case Report Word limit: 2,000 words maximum including an abstract in 250 words or less, key wormain text ≤ 2,000 words
- case reportspublishes articles on all aspects of Neuropsychopharmacology and its related fields in the following categories: Review Articles, Original Articles, Micro Repor…Length not stated
- commentarying recent articles in this journal. J. Commentary [BY INVITATION OR AFTER PROPOSAL OUTLINE] Word limit: 2,000 words maximum including an abstract in 250 words …main text ≤ 2,000 words
- micro reportspublishes articles on all aspects of Neuropsychopharmacology and its related fields in the following categories: Review Articles, Original Articles, Micro Repor…Length not stated
- micro reviewspublishes articles on all aspects of Neuropsychopharmacology and its related fields in the following categories: Review Articles, Original Articles, Micro Repor…Length not stated
- original articlespublishes articles on all aspects of Neuropsychopharmacology and its related fields in the following categories: Review Articles, Original Articles, Micro Repor…Length not stated
- protocolpublishes articles on all aspects of Neuropsychopharmacology and its related fields in the following categories: Review Articles, Original Articles, Micro Repor…Length not stated
- registered reportspublishes articles on all aspects of Neuropsychopharmacology and its related fields in the following categories: Review Articles, Original Articles, Micro Repor…Length not stated
- reviewbutions. References: up to 30. E. Micro Review Word limit: 2,000 words maximum including an abstract in 250 words or less, key wormain text ≤ 2,000 words
- review articlespublishes articles on all aspects of Neuropsychopharmacology and its related fields in the following categories: Review Articles, Original Articles, Micro Repor…Length not stated
- technical notestatement, and author contributions. H. Technical Note Word limit: 4,000 words maximum including an abstract in 250 words or less, key wormain text ≤ 4,000 words
Policy excerpts from the journal's websiteAuthorship, Conflicts of interest, Data availability, Publication ethics, Open access, Peer review, Plagiarism, Preprints
- Authorship
Authorship follows ICMJE criteria. Model summary
Neuropsychopharmacology Reports follows the recommendations formulated by the International Committee of Medical Journal Editors regarding criteria for authorship.
Source ↗Publisher website ·- Conflicts of interest Disclosure statement
Word Count: Word limit: 4,000 words maximum including an abstract in 250 words or less, key words, text, acknowledgments, disclosure statement, and author contributions.
Source ↗Publisher website ·- Data availability Data Sharing and Data Availability
Data sharing required as condition of publication; data availability statement required. Model summary
Neuropsychopharmacology Reports requires, as a condition for publication, that the data supporting the results in the paper will be archived in an appropriate public repository. Authors are required to provide a data availability statement, including a link to the repository they have used, and to cite the data they have shared. Whenever possible the scripts and other artefacts used to generate th…
Source ↗Publisher website ·- Publication ethics
Follows COPE core practices. Model summary
This journal follows the core practices of the Committee on Publication Ethics (COPE) and handles cases of research and publication misconduct accordingly
Source ↗Publisher website ·- Open access Open Access Agreement (OAA)
If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper. The following license agreements are available:Creative Commons Attribution Non-Commercial …
Source ↗Publisher website ·- Peer review
Member of Neuroscience Peer Review Consortium. Model summary
Neuropsychopharmacology Reports is a member of the Neuroscience Peer Review Consortium (NPRC).
Source ↗Publisher website ·- Plagiarism
Plagiarism screening via iThenticate CrossCheck. Model summary
This journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts.
Source ↗Publisher website ·- Preprints
Preprint policy: journal considers preprint submissions; authors may post submitted version to preprint server at any time. Model summary
This journal will consider for review articles previously available as preprints. Authors may also post the submitted version of a manuscript to a preprint server at any time.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Wiley-Blackwell
- Country or region
- Australia
- Language
- English
- ISSN
- 2574-173X
- Society / sponsor
- Japanese Society of Neuropsychopharmacology and Japanese Society of Clinical Neuropsychopharmacology
- Latest issue on the website
- Volume 46, Issue 3 (September 2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Neuropsychopharmacology Reports
What CAS zone is Neuropsychopharmacology Reports in?
In the 2025 upgraded edition of the CAS Journal Ranking, Neuropsychopharmacology Reports is in Zone 4 of Medicine, and in Zone 4 of the minor category Neurosciences / Pharmacology & Pharmacy / Psychiatry. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Neuropsychopharmacology Reports?
The journal's website gives an impact factor of 1.9 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 2.9, h-index 31.
How long does peer review take at Neuropsychopharmacology Reports?
Based on the dates recorded on 89 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 114 days (interquartile range 82–192 days); authors report an average review time of about 14 weeks; the journal's website gives an acceptance rate of 77% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Neuropsychopharmacology Reports?
According to the journal's author guidelines: Abstract: ≤ 250 words; Manuscript length: ≤ 4,000 words; Reference style: Author–date; Suggested reviewers: Optional; Highlights: Required; Graphical abstract: Optional; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Neuropsychopharmacology Reports based?
Of the 44 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Japan (30), United States (5) and Taiwan, China (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Neuropsychopharmacology Reports?
According to LetPub and DOAJ records, Neuropsychopharmacology Reports is indexed in ESCI, Scopus and DOAJ. The journal's website also lists Web of Science, MEDLINE, PubMed and Embase; that list has not been checked against each database.
Is Neuropsychopharmacology Reports open access, and what is the APC?
Neuropsychopharmacology Reports is a fully open-access journal. APC about USD 2,500.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .